Lomefloxacin Hydrochloride Production Cost Reports

The report provides detailed analysis essential for establishing a lomefloxacin hydrochloride production plant. It encompasses all critical aspects necessary for lomefloxacin hydrochloride production, including the cost of lomefloxacin hydrochloride production, lomefloxacin hydrochloride plant cost, lomefloxacin hydrochloride production costs, and the overall lomefloxacin hydrochloride production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a lomefloxacin hydrochloride production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Lomefloxacin Hydrochloride Market Analysis: Demand and Supply Analysis, and Sourcing

Lomefloxacin hydrochloride is a second-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase. It is the monohydrochloride salt of difluoromethyloxypiperazinyl quinolone carboxylic acid, with a molecular weight of about 387.8. Japan's Hokuriku Seiyaku discovered the drug, and Searle licensed it for the US, where the FDA approved Maxaquin 400 mg tablets in February 1992. Demand for lomefloxacin hydrochloride is now concentrated mainly in China, India, and other Asian and emerging markets. It is used more often in eye and ear drops than in tablets. In many Western markets, newer antibiotics have replaced it in routine treatment. Today, it is mainly sold as a low-cost generic through distributors, government tenders, and retail pharmacy chains.

Demand comes from manufacturers of eye drops, ear drops, and tablets, as well as hospitals and retail pharmacies across Asia, the Middle East, and parts of Africa. Lomefloxacin eye drops at a concentration of 0.3% are used to treat bacterial conjunctivitis and other eye infections. Ear drops are prescribed for certain ear infections. These products are sold through pharmacies, clinics, and hospital dispensaries, usually at low prices and in large quantities. Oral tablets are still used for urinary tract infections and flare-ups of chronic bronchitis in markets where they are approved. However, concerns about sensitivity to sunlight, nerve and tendon problems, and antibiotic resistance have reduced their use. China supplies most of the active pharmaceutical ingredient (API), while Indian manufacturers and chemical suppliers also cater to demand, especially for smaller orders and laboratory work. A lomefloxacin hydrochloride demand and supply analysis must weigh eye drop volumes, tender pricing, fluoroquinolone safety rules, stewardship programs, and intermediate supply. Buyers check assay, related substances, residual solvents, water content, heavy metals, and microbial limits on receipt. Most orders are modest, ranging from a few hundred kilograms to a few tons per customer per year, usually under annual contracts with fixed specifications, agreed impurity limits, and quarterly deliveries.

Summary of the Product, Grades, and Uses

Lomefloxacin hydrochloride is a white to off-white crystalline powder with a slightly bitter taste. It melts with decomposition at about 290 to 300 degree Celsius and dissolves readily in dilute alkali. The free base has the formula C17H19F2N3O3 and a molar mass of about 351.4. Its elimination half-life runs about seven to eight hours, which suits once-daily oral dosing. The methylpiperazine ring carries one stereocenter, and the drug is used as the racemic mixture, so no chiral separation is needed. That keeps the final stages simpler and cheaper than for single-enantiomer fluoroquinolones such as levofloxacin.

Lomefloxacin hydrochloride reaches the market as an API and in several finished forms. Pharmacopeial API grade meets Chinese, Indian, and other national monographs. Eye drops are usually 0.3% solutions, formulated with buffers, glycerin, sodium chloride, and a preservative such as benzalkonium chloride. Ear drops and 400 mg oral tablets complete the range. Buyers check assay, impurities, residual solvents, water, color, and particle size against the specification. Drop producers also look closely at solution clarity, since any haze shows up in a clear eye product.

Lomefloxacin hydrochloride is used mainly against Gram-negative bacteria. It covers many urinary and eye pathogens, including Escherichia coli, Klebsiella, Pseudomonas, & Hemophilus species. It is weaker against Streptococcus pneumoniae, which kept it out of pneumonia treatment, and resistance has grown in several target organisms since launch. Hospitals, clinics, eye specialists, and retail pharmacies are the end buyers of the finished products.

Main End-Uses of Lomefloxacin Hydrochloride

Eye care is the main application for lomefloxacin hydrochloride. Eye drops are used to treat bacterial conjunctivitis, keratitis, and blepharitis, with strong demand in China and other Asian markets. Some manufacturers combine the drug with sodium hyaluronate to make the drops thicker, help them stay on the eye for longer, and reduce the bitter taste that can occur when the medicine drains into the nose. These formulations are designed to improve absorption, reduce how often the drops need to be used, and make treatment easier for patients. Buyers mainly look for affordable prices, good solubility, suitability for sterile filtration, and a reliable supply. Since eye drops are usually sold in small bottles of 5 or 10 mL, a kilogram of the active ingredient can be used to produce many packs.

Ear drops are another important application. They are used to treat conditions such as otitis externa and certain chronic middle ear infections. Manufacturers can often use the same API supply and filling lines for both eye and ear drops. Buyers expect consistent quality, clear solutions, and good solubility. Although demand is lower than in eye care, these products must still meet requirements for sterility, clarity, particle control, and preservative effectiveness.

Oral tablets account for a smaller share of demand, and their use has declined since the 1990s. Lomefloxacin tablets containing 400 mg of the base were previously used once daily for conditions such as urinary tract infections, flare-ups of bronchitis, and prevention of infection before transurethral surgery. Treatment courses generally lasted around 10 to 14 days. However, oral use has fallen in many markets because of concerns about light sensitivity, safety warnings for fluoroquinolone antibiotics, and competition from newer medicines in the same class. Veterinary applications and research account for smaller volumes. Analytical laboratories also purchase reference materials for impurity testing, analytical method validation, and stability studies.

Lomefloxacin Hydrochloride Market Risks

Lomefloxacin hydrochloride carries market risk from safety concerns and competition from newer fluoroquinolones. Levofloxacin, moxifloxacin, gatifloxacin, and ofloxacin compete in both eye and oral markets. Regulators have added class warnings on tendon damage, nerve effects, and other serious reactions for fluoroquinolones. Stewardship programs limit routine use. Tender buying in China and India squeezes margins for both API and finished dose makers, and winning bids often turn on price, delivery record, and documentation quality rather than on product differences.

Lomefloxacin hydrochloride production carries its own risks because it is a multistep fluorinated API with tight purity limits. Fluorinated aromatic intermediates need careful handling and corrosion-resistant equipment. The piperazine coupling step can give positional isomers that are hard to remove later. Residual solvents and color bodies must be controlled to meet monograph limits. Most rejected lots trace back to related substances, isomer content, residual solvents, color, or water. A failed lot is costly, since the intermediate it was made from carries several steps of earlier value, including fluorination, ring formation, and purification work done upstream.

Lomefloxacin Hydrochloride Production Process and Main Cost Drivers

The lomefloxacin hydrochloride production process runs from a fluorinated quinolone carboxylic acid intermediate through coupling with methylpiperazine, isolation of the free acid, salt formation with hydrochloric acid, recrystallization, drying, milling, and packing.

1. By Coupling of the Fluoroquinolone Core with Methylpiperazine and Salt Formation: The main inputs are the difluoro quinolone carboxylic acid intermediate, 2-methylpiperazine, a polar reaction solvent, hydrochloric acid, activated carbon, recrystallization solvents & lined fiber drums.

Lomefloxacin hydrochloride production starts from a fluorinated quinolone carboxylic acid core. Manufacturers can either purchase the intermediate from suppliers or make it in-house using fluorinated aromatic starting materials and a series of ring-forming reactions. This decision affects production costs, waste generation, and the permits needed to run the plant. The intermediate is then reacted with 2-methylpiperazine, which replaces one of the ring's fluorine atoms and adds the required side chain. Careful control of this reaction helps limit the formation of unwanted positional isomers and reduces the amount of purification needed later.

Once the reaction is complete, the free acid is separated and treated with activated carbon to remove color. Hydrochloric acid is then added to form the hydrochloride salt. The product is recrystallized, filtered, washed, and dried under vacuum before being milled and sieved to the required particle size. Each batch is tested for assay, related substances, residual solvents, water content, and heavy metals according to the relevant monograph. At full yield, producing 1 kg of the salt requires approximately 0.70 kg of the quinolone acid core and 0.26 kg of methylpiperazine, based on stoichiometry. Production costs depend mainly on intermediate prices, reaction yield, control of unwanted isomers, and solvent recovery. Plants that manufacture several fluoroquinolone products can apply similar production methods and cost-saving measures across their product range.

Main Factors Affecting Lomefloxacin Hydrochloride Production Cost

As this lomefloxacin hydrochloride production plant report shows, lomefloxacin hydrochloride production cost is driven by the quinolone core intermediate. Building it requires several steps from fluorinated aromatics, so most of the value sits upstream of the final coupling. Manufacturers that purchase the core intermediate pay the supplier's margin but avoid the cost and waste associated with fluorination reactions. Methylpiperazine is used in smaller quantities, but it is a specialty amine and costs more than common solvents, acids, and bases. Losses during coupling, salt formation, and recrystallization increase the amount of raw material needed for each kilogram of finished product. Recovering product from mother liquors can reduce these losses, although the recovered material must be tested and checked before it can be reused.

Solvents, purification, and regulatory requirements account for much of the remaining production cost. Polar solvents must either be recovered through distillation or sent for incineration. Some product is also lost during carbon treatment and repeated recrystallization, including material left in spent carbon, filter cakes, and mother liquors. Wastewater containing fluoride and amines requires treatment before disposal. GMP requirements, impurity testing, and regulatory filings add to operating costs, particularly when production runs are small. Manufacturers must also continue audits, stability studies, and annual reporting even when sales remain unchanged. When production volumes decline, these fixed expenses are spread across fewer kilograms, increasing the cost per kilogram.

Raw Materials for Lomefloxacin Hydrochloride Production Plant and its Procurement

Raw material sourcing for lomefloxacin hydrochloride centers on the quinolone core and methylpiperazine. Most fluoroquinolone intermediates are supplied by fine chemical manufacturers in China and India. These companies usually supply materials used to make several drugs in the fluoroquinolone group, rather than focusing on a single product. Fluorinated aromatic starting materials are purchased from fluorochemical producers, while 2-methylpiperazine is sourced from specialty amine manufacturers. Hydrochloric acid, solvents, carbon, and packaging round out the inputs, and all of these are easy to buy in Chinese and Indian chemical markets.

The cheapest intermediate is not always the cheapest route to good lomefloxacin hydrochloride. Core material with isomer or dehalogenation impurities carries them into the final product. Methylpiperazine with water or related amines lowers yield and adds byproducts. In practice, intermediate purity, coupling control, carbon treatment, and crystallization drive most of the per-kilogram cost.

Lomefloxacin hydrochloride manufacturers manage supply through qualified intermediate vendors and GMP audits. Each lot is tested for assay, impurities, water, and appearance before it goes into production. Key starting materials are named in regulatory filings, so supplier changes need review and sometimes formal notice to regulators. Integrated makers that also produce other fluoroquinolones share these intermediates, spreading purchasing power, testing costs, and supplier audits across products.

Sustainability and Regulatory Requirements

Lomefloxacin hydrochloride production raises environmental concerns centered on solvents, fluoride salts, and antibiotic residues in wastewater. Regulators in China have tightened rules on antibiotic plant effluent. Solvents are recovered by distillation where quality allows, and recovered material is tested before reuse. Plants must neutralize and treat fluoride and salt loads before discharge, usually by adding lime, settling, and biological polishing. Antibiotic traces in effluent are a growing concern because they can drive environmental resistance, so plants use dedicated treatment, segregated drains, and regular monitoring. Spent carbon and filter cakes go to licensed handlers, with records kept for volumes, waste codes, transport, and disposal routes.

Regulatory obligations for lomefloxacin hydrochloride follow from its status as an antibiotic drug substance. API makers follow ICH Q7 GMP and meet the monograph that applies in each market. Many manufacturers have national product registrations, while some also maintain Drug Master Files (DMFs) for export markets. Eye and ear drops must be made under sterile conditions, while tablets must follow GMP requirements for solid medicines. Each product also needs approval from the relevant national regulatory authority before it can be sold. Fluoroquinolone antibiotics carry warnings about side effects such as tendon problems, nerve damage, and effects on the central nervous system. Lomefloxacin products also include warnings about increased sensitivity to sunlight. Rules on responsible antibiotic use influence how these medicines are marketed and prescribed. In some markets, fluoroquinolones are reserved for infections where other antibiotics are unlikely to work.

CAPEX and OPEX for a Lomefloxacin Hydrochloride Production Plant

A lomefloxacin hydrochloride plant is a small multipurpose API unit. Annual output is often only a few tons, run in short campaigns between other products. Investment starts with solvent storage, glass-lined reactors, and condensers for the coupling step. The plant also needs filtration and carbon treatment vessels, crystallizers, and centrifuges. The product is dried in vacuum dryers and then milled and sieved in a contained area. Supporting utilities include steam, chilled water, vacuum, nitrogen, and electricity. Solvent handling areas also need suitable explosion protection. The quality control lab should have HPLC and gas chromatography systems, a Karl Fischer titrator to measure moisture, and facilities for microbiological testing. The plant also needs a separate area for chemical reactions, a GMP-compliant area for finishing the product, and an effluent treatment plant to treat wastewater before disposal.

The main operating expenses for lomefloxacin hydrochloride come from raw materials and the steps involved in production. The quinolone core is usually the biggest cost, followed by 2-methylpiperazine, solvents, activated carbon, and packaging. Other expenses include staff wages, quality testing, wastewater treatment, and equipment maintenance. The final cost per kilogram depends on the price of the core intermediate, how much product is obtained from each batch, the batch size, and the amount of solvent that can be recovered and reused. In a lomefloxacin hydrochloride production plant project report, the lomefloxacin hydrochloride plant setup cost depends on capacity, how far back the plant integrates, solvent recovery scope, and finishing standards. On the running side, the biggest cost lines are intermediates, solvents, labor, and compliance. Plants that also make ofloxacin, levofloxacin, or ciprofloxacin spread their fixed cost better, a basic rule of industrial production economics. Shared reactors, solvent recovery, labs, and effluent plants lower cost per kilogram across the range.

Plant Location and Investment Factors

A lomefloxacin hydrochloride plant is best located in an API production hub near suppliers of fluoroquinolone intermediates. Zhejiang, Jiangsu, and Shandong in China, along with Gujarat, Maharashtra, and Telangana in India, have established chemical and pharmaceutical industries. The plant needs access to solvents, trained chemists, reliable steam and power, and a steady nitrogen supply. Antibiotic-related wastewater treatment facilities are also important. Before starting production, the company must obtain GMP certification, environmental clearance, solvent permits, and hazardous waste approvals. Being close to eye drop and tablet manufacturers can make sales, sample delivery, and technical support easier. Good access to ports is also useful for serving export markets in the Middle East, Africa, and Southeast Asia.

A key decision for a new lomefloxacin hydrochloride plant is whether to buy the quinolone core from suppliers or make it on-site. Buying it lowers the initial investment, but the plant depends on suppliers for consistent quality and pricing. Making it in-house requires extra equipment for fluorination, corrosion-resistant materials, and facilities to treat the additional waste. Manufacturers need to decide whether to sell the API alone or also set up filling lines for sterile eye and ear drops. New producers must ensure that raw materials are available when needed and that impurity levels stay within the required limits. They also need time to build trust with eye and ear drop manufacturers. Existing buyers may not switch suppliers just for a lower price, especially if they need to test the new API and complete required validation work. Switching an API supplier usually requires new validation batches, stability data, and regulatory filing updates.

Major Lomefloxacin Hydrochloride Producing Regions

China is the main source of lomefloxacin hydrochloride, with API and intermediate manufacturers spread across its eastern provinces. These areas also produce many of the intermediates used to make other fluoroquinolone antibiotics. India manufactures both the API and finished medicines, especially tablets for its domestic market and for export. Some pharmaceutical companies in the Middle East also make tablets for local demand. Although lomefloxacin was first developed in Japan, production there is now limited. Most of the API is packed in drums and supplied to companies that make eye drops, ear drops, and tablets across Asia and the Middle East. Since trade data rarely lists lomefloxacin separately from other fluoroquinolones, market activity is often assessed using supplier quotations and tender records.

Key Lomefloxacin Hydrochloride Producers

Hokuriku Seiyaku

• Japanese pharmaceutical company that discovered lomefloxacin.
• Licensed the drug to Searle for the US market.
• Held the original patents on the molecule.
• Competes on originator history & Japanese market presence.

Pharmacia

• Holder of the US Maxaquin tablet approval, now part of Pfizer.
• Marketed the 400 mg once-daily tablet after 1992 approval.
• The US listing is now discontinued.
• Competes no longer in this product, but set its clinical profile.

Kangya of Ningxia Pharma

• Chinese pharmaceutical company working on lomefloxacin eye drops.
• Holds a patent on a thickened 0.3% ophthalmic solution.
• Serves the Chinese ophthalmic market.
• Competes on formulation work & local supply.

Zhengzhou Ruikang Pharmaceutical

• Chinese pharmaceutical supplier listed for lomefloxacin hydrochloride.
• Offers the API to formulation manufacturers.
• Serves domestic and export buyers.
• Competes on price, with grade claims to be verified lot by lot.

Spectrum Chemical

• US supplier of laboratory and pharmaceutical grade chemicals.
• Lists lomefloxacin hydrochloride for research and analytical use.
• Serves labs and small-scale users.
• Competes on documentation & reliable small packs.

TCI

• Japanese fine chemical manufacturer with a large reagent catalog.
• Sells lomefloxacin hydrochloride at over 98% purity by liquid chromatography.
• Serves research labs worldwide.
• Competes on quality and global distribution.